このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy

2026年8月26日 更新者:Hua Huang, MD, PhD

A Prospective, Multicenter, Phase III Randomized Controlled Trial Evaluating the Impact of Radical Surgery Versus Non-Surgery on Prognosis and Quality of Life in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy (ALANO Study, CGCA2603 Study)

The goal of this clinical trial is to learn if radical surgery improves prognosis and quality of life compared with continued standard non-surgical treatment in gastric cancer patients with peritoneal metastasis who have achieved successful conversion therapy. The main questions it aims to answer are:

  • Does radical surgery prolong overall survival in patients who achieve successful conversion therapy?
  • Does radical surgery provide better or at least comparable quality of life and safety outcomes compared with continued standard treatment? Researchers will compare radical surgery versus continued standard systemic treatment to see whether radical surgery provides superior clinical benefit for patients after successful conversion therapy.

Participants will:

  • Initial laparoscopic exploration confirms CY0P1 or CY1P1, absence of distant organ metastasis, a PCI ≤ 20, and presence or absence of ascites.
  • Receive conversion therapy (chemotherapy, targeted/immunotherapy, intraperitoneal therapy, etc.) per standard guidelines, tailored to the patient's condition and molecular-pathological profile
  • If clinical conversion is confirmed, undergo a second laparoscopic exploration to verify successful conversion
  • If successful conversion is confirmed (peritoneal lesions cleared or markedly regressed with negative biopsy, no ascites or distant metastases, R0-resectable primary tumor, and improved patient condition), be randomized 1:1 to either the surgery group or the standard treatment group
  • In the surgery group, undergo curative gastrectomy with D2 lymphadenectomy during the second laparoscopy, followed by adjuvant therapy and maintenance treatment
  • In the standard treatment group, continue systemic therapy without surgery, with maintenance treatment and salvage surgery permitted if clinically indicated
  • Complete quality of life questionnaires at predefined time points
  • Be followed up for survival, disease progression, adverse events and medical resource use outcomes

調査の概要

研究の種類

介入

入学 (推定)

170

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100853
        • Chinese PLA General Hospital
        • コンタクト:
      • Beijing、Beijing Municipality、中国、102206
        • Peking University International Hospital
        • コンタクト:
      • Beijing、Beijing Municipality、中国、100142
        • Peking University Cancer Hospital
        • コンタクト:
    • Chongqing Municipality
      • Chongqing、Chongqing Municipality、中国、400038
        • The First Affiliated Hospital of Army Medical University
        • コンタクト:
    • Fujian
      • Zhangzhou、Fujian、中国、363000
        • Zhangzhou Affiliated hospital of Fujian Medical University
    • Guangdong
      • Guangzhou、Guangdong、中国、510060
        • Sun Yat-sen University Cancer Center
        • コンタクト:
      • Guangzhou、Guangdong、中国、510515
        • Nanfang Hospital, Southern Medical University
        • コンタクト:
      • Guangzhou、Guangdong、中国、510655
        • The Sixth Affiliated Hospital, Sun Yat-sen University
        • コンタクト:
    • Hubei
      • Wuhan、Hubei、中国、430030
        • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
        • コンタクト:
    • Jiangsu
      • Nanjing、Jiangsu、中国、210029
        • Jiangsu Province Hospital
        • コンタクト:
      • Nanjing、Jiangsu、中国、210009
        • Jiangsu Cancer Hospital
        • コンタクト:
      • Nanjing、Jiangsu、中国、210008
        • Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medicine School
        • コンタクト:
      • Nantong、Jiangsu、中国、226001
        • Nantong First People's Hospital
        • コンタクト:
          • shichun feng
          • 電話番号:+86 0513-81111888
          • メール:fsc2200@126.com
    • Jiangxi
      • Nanchang、Jiangxi、中国、330006
        • The First Affiliated Hospital of Nanchang University
        • コンタクト:
      • Nanchang、Jiangxi、中国、330006
        • The Second Affiliated Hospital of Nanchang University
        • コンタクト:
      • Shangrao、Jiangxi、中国、334000
        • Shangrao People's Hospital
        • コンタクト:
    • Jilin
      • Changchun、Jilin、中国、130021
        • The First Hospital of Jilin University
        • コンタクト:
    • Liaoning
      • Dalian、Liaoning、中国、116011
        • The First Affiliated Hospital of Dalian Medical University
        • コンタクト:
    • Shaanxi
      • Xi'an、Shaanxi、中国、710061
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • コンタクト:
      • Xi'an、Shaanxi、中国、710038
        • The Second Affiliated Hospital of Airforce Military Medical University
        • コンタクト:
    • Shandong
      • Jinan、Shandong、中国、250021
        • Shandong Provincial Hospital
        • コンタクト:
      • Jinan、Shandong、中国、250014
        • The First Affiliated Hospital of Shandong First Medical University
        • コンタクト:
      • Qingdao、Shandong、中国
        • The Affiliated Hospital of Qingdao University
        • コンタクト:
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200032
        • Fudan University Shanghai Cancer Center
        • コンタクト:
        • 主任研究者:
          • Hua Huang, MD,PHD
      • Shanghai、Shanghai Municipality、中国
        • Shanghai General Hospital
        • コンタクト:
    • Shanxi
      • Changzhi、Shanxi、中国、046000
        • Changzhi People'S Hospital
        • コンタクト:
    • Tianjin Municipality
      • Tianjin、Tianjin Municipality、中国、300060
        • Tianjin Medical University Cancer Institute&Hospital
        • コンタクト:
    • Xinjiang
      • Ürümqi、Xinjiang、中国、830011
        • Affiliated Cancer Hospital of Xinjiang Medical University
        • コンタクト:
    • Zhejiang
      • Hangzhou、Zhejiang、中国、310022
        • Zhejiang Cancer Hospital
        • コンタクト:
      • Hangzhou、Zhejiang、中国、310009
        • The Second Affiliated Hospital Zhejiang University School of Medicine
        • コンタクト:
      • Hangzhou、Zhejiang、中国、310016
        • Sir Run Run Shaw Hospital, affiliated with Zhejiang University School of Medicine
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Patients voluntarily participate in the study, sign the informed consent form, and demonstrate good compliance.
  • Age ≥ 18 years and ≤ 70 years.
  • Histologically and/or cytologically confirmed gastric cancer.
  • No evidence of gastric outlet obstruction or intestinal obstruction.
  • No distant metastasis on imaging examination. Initial laparoscopic exploration confirms CY0P1 or CY1P1, without distant organ metastasis, with a recorded peritoneal carcinomatosis index (PCI) ≤ 20, and with either positive or negative ascites. Patients meeting these criteria are eligible for pre-enrollment. Following successful conversion therapy, a second laparoscopic exploration must confirm conversion to CY0P0, with no distant organ metastases and no regional lymph node metastases beyond the second station. Only upon meeting these criteria are patients formally enrolled in the study.
  • No prior chemotherapy, targeted therapy, or immunotherapy.
  • ECOG performance status score of 0-2.
  • Life expectancy ≥ 12 weeks.
  • Laboratory requirements: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L, platelet count ≥ 75 × 10⁹/L, hemoglobin ≥ 8 g/dL; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN); total bilirubin ≤ 1.5 × ULN. In the presence of liver metastases, AST and ALT ≤ 5 × ULN; Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance (CCr) ≥ 60 mL/min; International normalized ratio (INR) ≤ 1.5 × ULN; prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.

Exclusion Criteria:

  • Initial laparoscopic exploration reveals P0, or either of the two laparoscopic explorations reveals distant organ metastasis or distant lymph node metastasis.
  • Prior anticancer therapy, including chemotherapy, targeted therapy, or immunotherapy.
  • Hypertension that cannot be adequately controlled with antihypertensive medication (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg).
  • Active bleeding or coagulation disorder within 2 months prior to enrollment, bleeding tendency, or ongoing thrombolytic therapy, deemed by the investigator as unsuitable for enrollment.
  • Active cardiac disease within 6 months prior to treatment, including myocardial infarction, severe/unstable angina pectoris. Left ventricular ejection fraction (LVEF) < 50% on echocardiography, or poorly controlled arrhythmia.
  • Known allergy to immunotherapy agents, chemotherapy agents, or any of their excipients.
  • Pregnancy (positive pregnancy test prior to treatment initiation) or breastfeeding.
  • Active or uncontrolled severe infection: Severe infection within 4 weeks prior to enrollment (e.g., requiring intravenous antibiotics, antifungals, or antivirals); Known human immunodeficiency virus (HIV) infection; History of clinically significant liver disease, including viral hepatitis. For known hepatitis B virus (HBV) carriers, active HBV infection must be excluded, defined as HBV DNA positive (> 1 × 10⁴ copies/mL or > 2000 IU/mL); Known hepatitis C virus (HCV) infection with positive HCV RNA (> 1 × 10³ copies/mL), or other hepatitis, cirrhosis.
  • Urinalysis indicating proteinuria ≥ 2+, with 24-hour urine protein quantification > 1.0 g.
  • Any other condition deemed by the investigator as inappropriate for participation in this study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Surgery Group
Patients undergo curative gastrectomy with D2 lymphadenectomy (laparoscopic, robotic, or open) during second-look laparoscopy after successful conversion therapy. Postoperatively, they receive adjuvant systemic therapy (continuing the preoperative regimen or MDT-modified protocol) for up to 8 cycles total, followed by maintenance therapy for up to 1 year after randomization, or until disease progression, unacceptable toxicity, or withdrawal.
アクティブコンパレータ:Standard Treatment Group
Patients do not undergo surgery. They continue the original conversion regimen or an MDT-adjusted systemic therapy for a total of 8 cycles, followed by maintenance therapy for up to 1 year after randomization, or until disease progression, unacceptable toxicity, or withdrawal. Salvage surgery is permitted if clinically indicated.

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
Overall Survival (OS)
時間枠:Up to 3 years after randomization
Up to 3 years after randomization

二次結果の測定

結果測定
メジャーの説明
時間枠
Quality of Life (QoL) assessed by EORTC QLQ-C30 questionnaires
時間枠:Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
Quality of Life (QoL) assessed by EORTC QLQ-STO22 questionnaires
時間枠:Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
Pathological Complete Response (pCR) Rate
時間枠:At the time of radical surgery
At the time of radical surgery
R0 Resection Rate
時間枠:At the time of radical surgery
At the time of radical surgery
Complication-Free Survival
時間枠:Up to 3 years after randomization
Up to 3 years after randomization
Major Complication Rate
時間枠:Within 30 days and 90 days after surgery
Within 30 days and 90 days after surgery
Progression-Free Survival (PFS) and Peritoneal PFS
時間枠:Up to 3 years after randomization
Up to 3 years after randomization
Time to Peritoneal Re-dissemination
時間枠:Up to 3 years after randomization
Up to 3 years after randomization
Length of Hospital Stay
時間枠:Perioperative period
Duration of postoperative hospital stay, calculated from the date of surgical intervention to the date of hospital discharge, only applicable to participants receiving surgical treatment.
Perioperative period
Readmission Rate
時間枠:Within 30 days and 90 days post-surgery
Within 30 days and 90 days post-surgery
Treatment Interruption Rate
時間枠:Within 1-year after randomization
Within 1-year after randomization
Direct Medical Costs / Hospitalization Costs
時間枠:Baseline through study completion, an average of 3-years post-randomization
Direct medical costs are defined as all medical expenses directly related to the patient's care, including hospitalization, surgery, medications, laboratory tests, imaging examinations, and management of complications. Data will be collected continuously throughout the study period (from baseline until death or study completion) and aggregated at the end of the study.
Baseline through study completion, an average of 3-years post-randomization

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年10月1日

一次修了 (推定)

2031年10月1日

研究の完了 (推定)

2031年10月1日

試験登録日

最初に提出

2026年8月23日

QC基準を満たした最初の提出物

2026年8月26日

最初の投稿 (実際)

2026年8月27日

学習記録の更新

投稿された最後の更新 (実際)

2026年8月27日

QC基準を満たした最後の更新が送信されました

2026年8月26日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2606346-6-2608A

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual-participant-level raw data will not be shared externally. Aggregated study results will be published in peer-reviewed journals.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する